Crescendo Biologics
UK-based clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics using its proprietary Humabody® platform for next-generation cancer treatments.
Location
Cambridge, United Kingdom
Founded
2009
Investors
1
Categories
biotech, immuno-oncology, cell-therapy, t-cell-engagers, antibody-engineering
Notes
Crescendo Biologics is a clinical-stage immuno-oncology company focused on developing novel T cell enhancing therapeutics for cancer treatment. The company's proprietary Humabody® platform enables the creation of highly customizable antibody-like molecules that can be designed to engage and enhance T cell activity against tumors.
Based in Cambridge, UK, Crescendo is developing a pipeline of Humabody-based therapeutics and has established partnerships with major pharmaceutical companies to leverage its platform technology.
Team
- Peter Pack, Ph.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/peterpack
- Hélène Pollard - Chief Financial Officer
Additional Research Findings
- Portfolio company of Sofinnova Partners
- Humabody® platform technology
- T cell enhancing therapeutics
- Clinical-stage immuno-oncology programs
- Partnership with Takeda and other pharma companies
- Cambridge, UK headquarters
- Novel antibody engineering approach
- Focus on solid tumor treatment
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Sofinnova Partners | Paris, France | biotech-focused | seedseries-a+3 | 23 |